West Bound and Down

After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have,...

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support...

Tailwinds' Take: to quote CEO, RJ Tesi, "This award reinforces one of INmune Bio’s fundamental drug development tenets – by targeting the underlying biology,...

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Hello Fall!

What a difference a week makes. Last Saturday I was writing about an epic (for Tailwinds) stretch of performance and salivating over all the...

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering...

Tailwinds' Take: good news as INmune's INKmune program, which has shown great early stage data, is now protected. INMB continues to execute on two...

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a...

Tailwinds' Take: great news as we believe Quellor has a great opportunity to not only have a positive impact in Covid-19 but also the...

Goodbye August (almost)…

Okay, I know it's not the official end of August...that takes place on Monday. However, due to the fact that the month is basically...

Shaking Things Up…

One of my investors recently told me that he diversifies his portfolio on his own. The money I manage for him is meant to...

This Week at Tailwinds

Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell...

European Patent Granted Covering INmune Bio’s XPro1595

Tailwinds' Take: important to obtain a patent for the very large European market. XPro1595 has blockbuster potential for INMB. Very excited to see more...

OnTrak For A Great Year

Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth...

INmune Earnings Conference Call Transcript

David J. Moss Thank you Malika, and good afternoon everybody. We thank you for joining us for the call for INmune Bio’s second quarter 2020...

INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020

Tailwinds' Take: BTIG banked their recent financing and now is hosting them at a conference. Could research be coming soon? LA JOLLA, Calif, Aug. 03,...

July Recap, August Preview…Best Month Yet at Tailwinds

Here I am on my first plane flight since Covid became a word used in our everyday vernacular. Things seem pretty much the same...

INmune Bio, Inc. Prices Public Offering of Common Stock

Tailwinds' Take: we view this very favorably as the only "negative" in the INMB story was their lack of capital. They are now funded...

INMB’s XPro1595…A Potential Disease Modifying Therapy for Alzheimer’s

"When they reached the end of their 12 week trial, this family was willing to do anything to remain on the drug...because it had...

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in...

Tailwinds' Take: this is very positive data. The reduction in white matter is particularly encouraging as there is direct correlation between this reduction and...

Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595...

Tailwinds' Take: with the trial being open-label, INmune has been able to see the data all along. Therefore, one can assume that they are...

Happy 4th of July…A Review of June and Other Notes

With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the...

Summer is Coming

When you receive this newsletter, it will be June 21st, the official start of summer. Typically for stocks you have a summer doldrums, "sell...

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial...

Tailwinds' Take: first-in-man for their second product line is a major accomplishment for the Company. By targeting the innate immune system's NK cells, INKmune...

June Preview…Plus Much More!

May was another strong month for the market as the stimulus package and expectations for a strong re-opening of the economy kept the rebound...

This Week’s Recap: Skinny Trails, Anixa Looks Primed, Atomera Launching

As most readers know by now, I love mountain biking. It's great exercise and there's a tremendous thrill to hitting a difficult stretch of...

Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in...

Tailwinds' Take: the scientific publication linked here is a great summation of the potential of NK cells in fighting cancer. INMB's INKmune program has...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

Tailwinds' Take: submitting an IND for Covid-19 this month is the biggest potential near term driver, but there are lots of shots on goal...

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response...

Tailwinds' Take: further evidence of the broad-scale applications possible by reducing soluble TNF and associated inflammation. INB03 has the potential to be used in...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

The Eye Of The Storm…This Week In Tailwinds’ World

Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but...

Anixa and INmune: Unique COVID-19 Opportunities In Tailwinds’ Universe

CoronaVirus is not only the buzzword for the whole market both on the negative side as business falls off a cliff, and positively as...

This Week in Stocks

While the markets may not have had the most volatile week of the year, nor come close, it was a very topsy-turvy five days...

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer

Tailwinds' Take: more evidence on the negative role that soluble TNF plays in many diseases. INMB's ability to neutralize soluble TNF without associated immuno-supression...

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In...

Tailwinds' Take: patents show the uniqueness of INKmune, which is set to start two clinical trials this year. INMB is one of the most...

INmune Bio (INMD) Conference Call on COVID19 Program Transcript

INmune Bio DN-TNF Clinical Trial, Complications of Cytokine Storm Caused by COVID-19 April 20, 2020 Presenter R.J. Tesi, CEO and Chief Medical Officer David Moss, CFO Q&A Participants John Aschoff -...

INmune Addresses COVID-19

Monday morning, INmune Bio (INMB) announced that they were pursuing a clinical program to determine if the Company’s TNF Inhibitor (DN-TNF) platform could help...

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if...

Tailwinds' Take: this Phase II trial is going to happen quickly. Inflammation is a big part of the problems associated with CV19 and INmune's...

Saturday Morning Ramblings…

Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible?...

This Week In MicroCap

It was certainly a great week for the market as a number of positive factors contributed to the continuation of what is a very...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

It’s Definitely a Beer Market

Sometimes a typo can hit the sweet spot, right? When I got the text that we're entering a beer market...well, let's just say that...

INMB: INmune Bio Earnings Call Transcript

INmune Bio, Inc. Fourth Quarter and Full Year 2019 Earnings Call March 11, 2020, 11 AM  Presenters Landon Baretto, Moderator Raymond J. Tesi, MD, CEO David J....

INMB: Interview with Dr. CJ Barnum, Director of Neuroscience

INmune Bio (INMB) is developing a drug targeting the innate immune system and, specifically, its role in the development of chronic inflammation as humans...

Thoughts From Last Week

This feels like a very strange time in the market. Usually markets overreact to news. Violent swings to extreme levels are the common occurrence...

Thoughts From The Last Week…

Lots going on in Tailwinds' universe recently. Here I recap conversations and observations from the prior week's trading... This screen shot says it all...if Druck...

INmune Webinar Transcript: Bench to Bedside

R.J.: So, hello everybody, I'm R.J. Tesi. I'm the CEO and Acting Chief Medical Officer of Inmune Bio, and today I'll be hosting...

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate...

Tailwinds' Take: yet another disease where neuro-inflammation plays a role. The breadth of potential treatments for this product is staggering. LA JOLLA, Calif. , Feb....

Slogging Through Winter

I was skiing outside Seattle last weekend. Steven's Pass ski resort, to be precise. They have gotten a lot of snow up there this...

Wasn’t That An Amazing Sunset?

On Thursday this week, as we finished dinner I looked out the window and the sky was on fire. It was quite possibly the...

INmune’s Efforts in Alzheimer’s…Low Risk to Phase 1b Success???

In December of 2019, INmune Bio (INMB) commenced dosing of humans in a Phase 1b trial of XPro1595 (XPro), a drug targeting Alzheimer’s Disease....

What to Expect When Everyone’s Expecting (An Up Market)

What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us...

Nmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to...

Tailwinds' Take: more solid data that should translate very well into humans. Remember, INmune has an ongoing Phase 1b trial in Alzheimer's Disease right...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03,...

Tailwinds' Take: this is a very positive step for this platform. Next steps here are to start a Phase IIa open-label trial next summer,...

Introducing INmune Bio

We are initiating coverage today on INmune Bio (Nasdaq: INMB). According to the Company, INmune (INMB) is “Reprogramming the Innate Immune System for the...

INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study

Tailwinds' Take: this trial looks poised for success as XPro1595 is known to be safe and reduce inflammation, the endpoints for this trial design.  LA...

INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar

LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s...

Deep Fried Turkey

Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain...

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia...

LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune...

INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update

LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system...

INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer’s Disease at the...

LA JOLLA, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system...

INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer

LA JOLLA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.